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The increase of total choline in tumors has become an important biomarker in cancer diagnosis.
Choline and choline metabolites can be measured in vivo and in vitro using multinuclear MRS.
Recent in vivo 13C MRS studies using labeled substrates enhanced via dynamic nuclear
polarization demonstrated the tremendous potential of hyperpolarization for real-time metabolic
studies. The present study demonstrates the feasibility of detecting hyperpolarized 15N labeled
choline in vivo in a rat head at 9.4 T. We furthermore report the in vitro (172  16 s) and in vivo
(126  15 s) longitudinal relaxation times. We conclude that with appropriate infusion protocols
it is feasible to detect hyperpolarized 15N labeled choline in live animals.
1. Introduction
Many magnetic resonance spectroscopy (MRS) studies of
choline metabolism have shown increased levels of total Cho
(tCho) in cancers developing in diﬀerent organs, such as
brain,1–5 prostate6–8 and breast.9–13 The increase of tCho in
tumors has become a potentially important biomarker in
cancer diagnosis.14–16 Recent results have shown a signiﬁcant
decrease of tCho concentration in breast cancers responding to
chemotherapy.17 Overall, there is strong evidence suggesting
the importance of this biomarker in monitoring the response
to diﬀerent treatments such as radiotherapy, chemotherapy or
brachytherapy.17–20
Cho penetrates cell membranes and is a natural constituent
of blood.21 In addition, Cho is a precursor of various
metabolic pathways. In the brain, for example, choline
is a substrate of choline containing phospholipids and of
acetylcholine.22,23 However, in tumors Cho is integrated
mainly into phospholipids,21,22 a major constituent of cell
membranes. Cho is incorporated into cell membranes by
adenosine triphosphate (ATP) dependent phosphorylation
and transformed by choline kinase in phosphocholine
(PCho). Then, PCho is activated by the reaction with cytidine
triphosphate forming cytidine diphosphate (CDP)-choline.
Through phosphocholine transferase, PCho is transferred from
CDP-choline producing phosphatidylcholine and cytidine
monophosphate.
Although PET data reported that choline uptake into the
healthy brain is considered to be low relative to other organs
(kidney, liver, etc.),22,23 Klein et al.24–26 reported that free
choline is present in minute amounts in the brain, with a Cho
arterial-venous diﬀerence of max 88.6 mM corresponding to an
uptake of 70 nmol g1 of brain per minute. Normal brain cells
do not need much Cho for cell membrane formation because
they are in a non-dividing postmitotic state.22 Conversely,
increased cell membrane synthesis is present in brain tumors.
Hara et al.23 indeed observed high 11C choline uptake in brain
tumors. In addition, Shinoura et al.22 acquired PET data 5 min
after 11C Cho injection, showing incorporation of 11C Cho
into human brain tumors within 5 min. This high Cho uptake
in tumors is consistent with MRS measurements, in which
elevated concentrations of tCho were found in brain
tumors.1–5
Choline and choline metabolites can be measured in vivo
and in vitro, in diﬀerent organs and in cells using multinuclear
MRS. Proton MRS is a wildly used technique to investigate
the tCho amounts in diﬀerent organs both in vivo and in vitro.
The tCho signal, which is detected by 1H MRS at B3.2 ppm
represents a combination of three signals: free choline, PCho
and glycerophosphocholine. Phosphorus MRS is another
option for detecting 31P-containing choline compounds. In
addition, it is also feasible to label choline nuclei with e.g. 13C,
2H and 15N and then monitor the incorporation of the label
into choline metabolites.27 However, the low natural abundance
of e.g. 15N (0.365%) makes the study of nitrogen metabolism
diﬃcult. The study of nitrogen metabolism by 15N MRS
requires the continuous infusion for several hours of a 15N
labeled substrate.28,29 The recently developed hyperpolarization
technique based on dynamic nuclear polarization30 opened
new perspectives for metabolic studies using heteronuclei since
the NMR signal-to-noise ratio is enhanced by up to four
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orders of magnitude.31 The main limitation of the technique is
that in vivo studies are only possible on nuclei with long
longitudinal relaxation times (T1), and so far carboxyl
13C
nuclei (e.g. pyruvate, acetate and bicarbonate) have been the
most promising candidates.32–35 Previous studies have shown
the utility of this technique for detecting in vivo tumors in
animal models36,37 and very low contrast agent concentrations.38
To date, besides optically polarized 3He and 129Xe,39 6Li is
the only hyperpolarized nucleus besides 13C that has been
reported to be detected in vivo.38 Two recent studies reported
remarkably long in vitro longitudinal relaxation times for 15N
Cho,40,41 suggesting that hyperpolarized 15N Cho could be a
suitable candidate for in vivo experiments.
However, the rapid bolus administration of Cho requires an
approach compatible with its toxicity to lungs and mucous
membrane. To our knowledge the in vivo detection of
hyperpolarized 15N Cho has not been demonstrated to date
and we report here the ﬁrst in vivo study using DNP-enhanced
15N nuclei.
The aim of the present study was twofold: (1) to demon-
strate the feasibility of detecting DNP-enhanced 15N labeled
Cho in vivo in a rat head and (2) to measure T1 relaxation
times in vivo.
2. Results and discussion
The time evolution of the 15N solid-state polarization was
measured at 1.2 K using a dedicated home-built NMR spectro-
meter and a remotely tuned and matched low-temperature
NMR probe.42 The polarization time constant was 2700 200 s.
Fig. 1 shows an example of a representative 15N Cho
polarization curve. The 15N solid-state polarization was
enhanced by DNP for 2.5 h prior to performing the dissolution
step. The maximum solid-state polarization was measured to
be 3.3  0.3%. This value, which was conﬁrmed by the
comparison between the liquid-state thermal equilibrium signal
intensity and the hyperpolarized signal measured immediately
after dissolution, corresponds to a signal enhancement of
10 000  900 if compared to the room-temperature thermal
equilibrium signal in a ﬁeld of 9.4 T. Nearly the same
enhancement factor was reported by Gabellieri et al.41 at
9.4 T, using a commercial DNP polarizer working at 3.35 T
and 1.4 K with trityl radicals as polarizing agent.
As can be seen in Fig. 2, the in vitro 15N Cho signal
remained visible for B800–900 s. Taking into account RF
pulse eﬀects, the apparent in vitro T1 was estimated to be
172  16 s (n = 4). The correlation coeﬃcients were between
0.91–0.99.
Due to the toxicity of Cho to lungs and mucous membrane,
it was necessary to determine the maximum concentration
that can be infused while maintaining the animal within
normal physiological ranges. This was established in bench
experiments designed to simulate the injection performed in
the rat by the external pump immediately after the DNP
dissolution (2.5 ml injected into the rat femoral vein over 9 s).
At concentrations of B90 mM, the rats remained physio-
logically stable allowing at least two subsequent injections on
the same animal.
Fig. 3 displays a series of in vivo spectra of hyperpolarized
15N Cho. The in vivo 15N Cho signal was discernible above the
noise level forB100 s despite the repeated RF pulsing at 101,
with in vivo linewidths of 9  2 Hz. The characteristic in vivo
T1 was 126  15 s (n = 5), after correcting for RF ﬂip angle
eﬀects. The correlation coeﬃcients were between 0.91–0.99.
The in vivo signal-to-noise ratio (SNR) was approximately
10-fold lower compared to the in vitro experiments, as a
consequence of the lower Cho concentration in the sensitive
volume of the coil.
The present study demonstrates for the ﬁrst time the
feasibility of detecting hyperpolarized 15N labeled Cho
in vivo in a rat head. Hyperpolarized 15N Cho was admini-
strated two consecutive times to the same animal at a
concentration of B90 mM, showing that hyperpolarized
15N Cho can be administered and subsequently detected in vivo.
Fig. 1 15N polarization curve recorded at 1.2 K prior to dissolution
using 5 degree RF pulses. The build-up time constant was 2700 200 s
and the polarization prior to dissolution was 3.3  0.3%.
Fig. 2 (a) Series of spectra of hyperpolarized in vitro 15N Cho
measured in a phantom. The signal is visible up to B800–900 s after
dissolution. Individual spectra were processed with 10 Hz Lorentzian
line broadening. The 15N chemical shifts were referenced to nitro-
methane. (b) Decay curve of the same in vitro signal amplitudes (black
dots) corrected for the RF ﬂip angle eﬀects. The ﬁt of the plotted decay
curve is also shown (line).






























































We furthermore report the in vitro and in vivo longitudinal
relaxation times at 9.4 T. Our in vitro results in a phantom
(T1 = 172  16 s) were in good agreement with the in vitro
values of 189  2 s and 203  10 s reported in previous 15N
hyperpolarized Cho studies performed in high-resolution
NMR systems.40,41
In vivo relaxation times showed a decrease compared with
the in vitro values, which can be explained by the fact that the
relaxation times of metabolite are likely to be inﬂuenced by the
microenvironment.43 In addition, the in vivo relaxation times
exhibited a deviation from the standard mono-exponential
decay, with a very fast decay (6  1.5 s) during the ﬁrst
seconds, followed by a slower decay afterwards (126  15 s).
This was very unlikely due to the presence of TEMPO, which
can act as a relaxing agent within the ﬁrst seconds, since this
was not observed in vitro. Eﬀects related to the presence of
deoxygenated and oxygenated blood are also unlikely to be the
cause, since the bolus passes ﬁrst through the heart and
thereafter to the lungs where it becomes oxygenated before it
reaches the brain. It is also unlikely that instability issues in the
ﬁrst seconds after the injection related to the animal reaction
to the bolus shorten the T1 since during bench and MR
experiments animals were behaving normally. Therefore, the
bi-exponential decay likely reﬂects the presence of Cho ﬁrst in
the blood and afterwards in the brain due to uptake. By
infusing 90 mM of Cho into the femoral vein, the Cho
concentration into the blood is estimated at B5 mmol ml1
(blood and interstitial volume of 10% of the body weight,
http://www.ahc.umn.edu/rar/BLOOD.HTML). Considering a
cerebral blood volume of B3%,44 the apparent tissue Cho
concentration would amount to a signal originating from an
apparent tissue concentration of B150 nmol g1 (speciﬁc
weight of B1 g ml1). An uptake of 70 nmol g1 of brain
min1 has been reported,24–26 consequently after B40 s we
should have (neglecting eﬄux) B50 nmol g1 of Cho in the
brain, which represents one-third of the observed Cho signal.
From these considerations it appears likely that a signiﬁcant
fraction of the Cho signal arises from the cerebral compartment,
in addition to the blood pool. Further investigations have to
be performed in order to precisely assess the amount of the
MRS choline signal originating from brain and from the
blood pool.
Although Cho uptake into the healthy brain is considered to
be lower relative to the uptake of other organs,22,23 it is of
interest to note that all 11C Cho PET studies imaging brain
tumors showed a very high uptake of 11C Cho in brain tumors.
Compared to 15N choline, 11C choline has a half-life ofB20 min
and the dose injected in rats is B0.2 ml (0.3–0.4 GBq).22
However, recent studies have shown that 15N in deuterated
choline40 has a lifetime of only 3 times less than that of
11C-choline. In addition, our data suggest that with an uptake
of 70 nmol g1 of brain min1 24–26 it is very possible that a
suﬃcient fraction of Cho enters the brain, so that it becomes
detectable before the in vivo hyperpolarized 15N Cho signal
disappears in the noise (i.e.within a time window of about 100 s).
Consequently, since total Cho becomes an important
biomarker in cancer diagnosis, the long T1 obtained in our
study combined with the potential to observe hyperpolarized
15N Cho in vivo makes this compound useful for early detection
of tumors. Thus, hyperpolarized 15N Cho could become an
alternative MR technique to PET imaging with 11C choline.
Moreover, due to the long in vivo T1,
15N Cho could be used to
Fig. 3 (a) Plot of the ﬁrst 31 in vivo 15N Cho spectra over time. Individual spectra were processed with 10 Hz Lorentzian line broadening. The 15N
chemical shifts were referenced to nitromethane. (b) Decay curve of the same in vivo signal amplitudes (black dots) corrected for RF ﬂip angle
eﬀects. The ﬁt of the plotted decay curve is also shown (line).






























































detect very low contrast agent concentrations, as has been
shown previously for 6Li by van Heeswijk et al.38 Hyper-
polarized 15N Cho could also be potentially used in the
assessment of blood ﬂow.
For a given and equal polarization, the SNR should be
about 2.5 times smaller for 15N than for 13C since it should be
proportional to the gyromagnetic ratio times the nuclear
polarization if the main source of noise in the experiment is
originating from the sample, as is the case for most MR
experiments in ﬁelds above 1T.45 At a given time, the SNR
depends on the longitudinal relaxation time, which was in the
present in vivo 15N study on the order ofB5 times longer than
the typical 13C characteristic decays observed in vivo.46,47
Therefore, despite the lower sensitivity of nitrogen, its longer
decay time should allow to probe biological processes on an
extended time scale. The relatively long T1 of
15N may render
other nitrogen compounds suitable for DNP-enhanced
in vivo metabolic studies. 15N MRS labeled experiments are
particularly useful for measuring the rates of synthesis of




For the hyperpolarization of 15N Cho, 98% 15N enriched
choline chloride (Sigma Aldrich, St. Louis, MO) solution
was prepared at a concentration of 6 M in a 60/40 v/v
deuterated water/glycerol solvent doped with 50 mM of
TEMPO (2,2,6,6-tetramethyl-1-piperidinyloxy, 98% purity,
Sigma-Aldrich, St. Louis, MO) as polarizing agent. This
solution was polarized at 3.35 T and 1.2 K using a custom-
built polarizer described by Comment et al.35,48 The output
power of the 94 GHz microwave source was set to 30 mW.
After dissolution into 5 ml of superheated D2O pressurized at
10 bars, the solution was automatically transferred within 4 s
to a phase separator/infusion pump placed in the bore of
the 9.4 T system positioned approximately 4 m away from the
DNP polarizer. An external pump subsequently drove the
injection of 2.5 ml of the hyperpolarized solution into the rat
femoral vein over 9 s. The concentration of the 15N Cho
infusate wasB90 mM. This concentration corresponds to the
maximum concentration that can be infused while maintaining
the animal within normal physiological ranges. It was determined
through bench experiments with non-hyperpolarized and
non-labeled Cho solution using the infusion system designed
for the DNP experiments. At least two consecutive injections
of hyperpolarized 15N Cho separated by a delay of 3 h could
be performed on the same animal. Note that the residual
radicals (about 0.8 mM) were not ﬁltered out of the hyper-
polarized solution. TEMPO is however known to have low
toxicity49 and nitroxyl radicals are in fact used as in vivo
antioxidants.50–52
Animals
All animal experiments were conducted according to federal
and local ethical guidelines and the protocols were approved
by the local regulatory body.
For the in vivo experiments, male Sprague-Dawley rats
(n = 5, B400 g) were anesthetized using 1.5% isoﬂurane.
One femoral vein and one artery were cannulated for 15N
choline chloride injection and blood sampling (monitoring
blood gases and pH), respectively. Approximately 0.1 ml of
blood was used to measure physiological parameters with an
AVL Compact 3 pH/blood gas analyzer (Roche Diagnostics
GmbH, Germany). The pH and blood gases were maintained
within normal physiological ranges (mean pH  SD =
7.31  0.04; mean pCO2  SD = 43.5  1.8). During the
MRS experiments, respiration rate and blood pressure
were monitored using a small-animal monitoring system
(SA Instruments Inc., New York, NY, USA) and maintained
within a normal range. Body temperature was measured using
a rectal thermosensor and maintained at 38.0  0.5 1C by
circulating warm water through tubes around the animal. The
physiological parameters remained within normal physiological
ranges after the choline bolus injection. During the bolus
injection the respiration rate slowed down by B 10%, but
recovered to normal in the next few minutes.
15N MRS
In vitro and in vivo 15N spectra were measured on a Varian
Inova spectrometer (Palo Alto, Ca, USA) interfaced to an
actively-shielded 9.4 Tesla magnet (Magnex Scientiﬁc, Oxford,
UK) with a 31 cm horizontal bore and 12 cm id gradient sets
giving a maximum gradient strength of 400 mT m1 in 120 ms.
A home-built 14 mm diameter 1H quadrature surface coil
combined with a 5 loops-10 mm diameter 15N surface coil
placed on the head of the animal was used for transmission
and reception. A time dependent quantitative eddy current
ﬁeld mapping53 was used for eddy currents minimization. First
and second-order shims were adjusted using FASTESTMAP.54
Images for localization were obtained in the coronal plane
using a multislice fast spin echo sequence with TE/TR =
60/5000 ms, slice thickness = 1 mm, FOV = 25  25 mm,
matrix = 256  256 and 2 averages. The in vitro and in vivo
acquisitions were performed using a 3 ms 101 BIR4 pulse55
with 10 and 3 s interpulse delay, respectively. The scanning
time of the in vivoMRS experiment was 600 s (200 acquisitions
with TR = 3 s). The 15N in vivo and in vitro signals were ﬁtted
using AMARES (advanced method for accurate, robust, and
eﬃcient spectral ﬁtting)56 from the jMrui software.57 The
signals were Lorentzian line broadened with 10 Hz, one
Lorentzian spectral component was selected to ﬁt the major
contribution of the metabolite, the zero-order phase was
estimated and the ﬁrst-order phase was ﬁxed to zero for each
signal of the time series. The accuracy of the amplitude
estimates was assessed using the Crame´r-Rao lower bounds.58
Then, the in vitro and in vivo longitudinal relaxation times were
determined from the hyperpolarized signal decay corrected
for the magnetization loss due to the RF excitations by
dividing the signal amplitude after the nth excitation
pulse by cos(101)n1, where n represents the number of
excitations. The correlation coeﬃcients reﬂecting the quality
of the least squares ﬁt vs. the original data were computed for
each ﬁt. A typical standard error of the ﬁtted T1 was
about 5%.































































We conclude that with appropriate infusion protocols it is
feasible to detect hyperpolarized 15N labeled Cho in live
animals. To the best of our knowledge, the present manuscript
reports the ﬁrst in vivo detection of a DNP-enhanced
15N-substrate. The generally long longitudinal relaxation
times of 15N nuclear spins that are not directly bound to
protons make these nuclei very attractive for in vivo applications
using hyperpolarized biomolecules.
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